Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | LYKALABS Lyka Labs Limited Pharma · Small | NECLIFE Nectar Lifesciences Limited Pharma · Small | LOTUSEYE Lotus Eye Hospital and Institute Limited Pharma · Small | VINEETLAB Vineet Laboratories Limited Pharma · Small |
|---|---|---|---|---|
| Final Score | 22 | 28 | 13 | 2 |
| Verdict | OVERVALUED | OVERVALUED | OVERVALUED | OVERVALUED |
| Style | OVERVALUED | OVERVALUED | OVERVALUED | Distress Watch |
| Piotroski | 6/9 | 4/9 | 6/9 | 2/9 |
| Valuation | 5/30 | 5/30 | 1/30 | 3/30 |
| Growth | 6/25 | 4/25 | 4/25 | 0/25 |
| Quality | 0/20 | 0/20 | 0/20 | 0/20 |
| Balance Sheet | 7/15 | 11/15 | 4/15 | 0/15 |
| Cash Flow | 4/10 | 9/10 | 4/10 | 7/10 |
| Price | ₹70.05 | ₹11.83 | ₹122.39 | ₹33.71 |
| P/E | — | — | 3065.00 | — |
| P/B | 2.46 | 0.39 | 4.08 | 4.70 |
| ROE | -10.20% | -7.46% | 0.13% | -89.50% |
| ROCE | -6.10% | -4.88% | 1.16% | -28.00% |
| Debt / Equity | 0.53 | 0.00 | 0.26 | 3.07 |
| FCF Yield | — | 380.09% | — | 11.98% |
| Dividend Y | — | — | — | — |
| Altman Z | 2.96 | 4.68 | 7.71 | 1.08 |
| Promoter % | 58.16% | 51.84% | 40.14% | 5.98% |
| Mkt Cap (₹Cr) | 227.00 | 226.00 | 245.00 | 66.80 |
| Graham # | — | — | ₹5.1 | — |
| Fair PE | 8.7 | 5.8 | 1.0 | 4.2 |
| MoS % | — | — | -308965.7% | — |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startLYKALABS47
NECLIFE32
LOTUSEYE183
VINEETLAB58